Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
| ▸ | BUB1 | O43683 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21997760 | 0.85 | HSD11B1 (0.38) | HSD11B1ASGR1DDB1CRBNKDM4D | |
| SCHEMBL21998016 | 0.81 | HSD11B1 (0.36) | HSD11B1ASGR1DDB1CRBNKDM4D | |
| SCHEMBL22848661 | 0.80 | HSD11B1 (0.40) | HSD11B1ASGR1DDB1CRBNKDM4D | |
| SCHEMBL25327534 | 0.78 | HSD11B1 (0.42) | HSD11B1ASGR1DDB1CRBNKDM4D | |
| SCHEMBL22835355 | 0.77 | HSD11B1 (0.38) | HSD11B1ASGR1DDB1CRBNKDM4D | |
| SCHEMBL21997430 | 0.76 | HSD11B1 (0.38) | HSD11B1ASGR1DDB1CRBNKDM4D | |
| SCHEMBL190837 | 0.75 | HSD11B1 (0.47) | HSD11B1ASGR1DDB1CRBNKDM4D | |
| SCHEMBL1058050 | 0.75 | HSD11B1 (0.43) | HSD11B1ASGR1DDB1CRBNKDM4D | |
| SCHEMBL27849879 | 0.75 | HSD11B1 (0.40) | HSD11B1ASGR1DDB1CRBNKDM4D | |
| SCHEMBL228179 | 0.74 | HSD11B1 (0.46) | HSD11B1ASGR1KDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885ASGR1 2610/4885DDB1 1267/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885ASGR1 2610/4885DDB1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.